rs202184038
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The NM_003738.5(PTCH2):c.3269C>T(p.Ala1090Val) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000211 in 1,614,070 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 16/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Synonymous variant affecting the same amino acid position (i.e. A1090A) has been classified as Likely benign.
Frequency
Consequence
NM_003738.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PTCH2 | ENST00000372192.4 | c.3269C>T | p.Ala1090Val | missense_variant | Exon 21 of 22 | 1 | NM_003738.5 | ENSP00000361266.3 | ||
PTCH2 | ENST00000447098.6 | c.3269C>T | p.Ala1090Val | missense_variant | Exon 21 of 23 | 1 | ENSP00000389703.2 | |||
PTCH2 | ENST00000438067.5 | c.29C>T | p.Ala10Val | missense_variant | Exon 2 of 5 | 3 | ENSP00000413169.1 |
Frequencies
GnomAD3 genomes AF: 0.000151 AC: 23AN: 152128Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000155 AC: 39AN: 250814Hom.: 0 AF XY: 0.000184 AC XY: 25AN XY: 135666
GnomAD4 exome AF: 0.000217 AC: 317AN: 1461824Hom.: 0 Cov.: 33 AF XY: 0.000234 AC XY: 170AN XY: 727208
GnomAD4 genome AF: 0.000151 AC: 23AN: 152246Hom.: 0 Cov.: 32 AF XY: 0.000134 AC XY: 10AN XY: 74440
ClinVar
Submissions by phenotype
Basal cell carcinoma, susceptibility to, 1 Uncertain:1
- -
Gorlin syndrome Uncertain:1
This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 1090 of the PTCH2 protein (p.Ala1090Val). This variant is present in population databases (rs202184038, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with PTCH2-related conditions. ClinVar contains an entry for this variant (Variation ID: 453937). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt PTCH2 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Basal cell nevus syndrome 1 Uncertain:1
The PTCH2 c.3269C>T (p.Ala1090Val) missense change has a maximum subpopulation frequency of 0.026% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org). The in silico tool REVEL predicts a benign effect on protein function, but this prediction has not been confirmed by functional studies. This variant has not been reported in individuals with nevoid basal cell carcinoma syndrome. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at